Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DEPECA-1 – DEfeating PEnile CAncer 1
2025-521644-37-00Phase 2Authorised
- Sponsor
- Institut für Klinische Krebsforschung
- Start
- Oct 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of enfortumab vedotin and avelumab in penile squamous cell carcinoma (PSCC), sponsored by Institut für Klinische Krebsforschung. Primary endpoint: Objective Response Rate (ORR). Planned start Oct 2025; status: authorised.
02
Drugs
enfortumab vedotinavelumab
03
Conditions
penile squamous cell carcinoma (PSCC)
Beyond the preview
Go deeper on 2025-521644-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521644-37-00.